Corcept Therapeutics (CORT) Net Income (2010 - 2026)
Corcept Therapeutics (CORT) posted Net Income of $43.0 million for Q2 2026, up 235.54% sequentially from -$31.7 million in Q1 2026, and up 22.15% YoY from $35.2 million in Q2 2025.
Corcept Therapeutics (CORT) Net Income (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Net Income for 17 years, with the latest figure at $43.0 million in Q2 2026.
- Quarterly Net Income rose 22.15% year-over-year to $43.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $55.2 million (down 58.7% YoY) and the FY2025 annual result came in at $99.7 million, down 29.43% from the prior year.
- Net Income rose to $43.0 million in Q2 2026 per CORT's latest filing, from -$31.7 million in the prior quarter.
- Over five years, Net Income peaked at $47.2 million in Q3 2024 and troughed at -$31.7 million in Q1 2026.
- A 5-year average of $25.5 million and a median of $27.6 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2026: Net Income soared 89.07% in 2023, then sank 254.35% in 2026.
- Over 5 years, Net Income stood at $16.6 million in 2022, then surged by 89.07% to $31.4 million in 2023, then declined by 1.96% to $30.8 million in 2024, then declined by 21.08% to $24.3 million in 2025, then surged by 76.99% to $43.0 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered $43.0 million, -$31.7 million, and $24.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 42.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.99 Mn |
| Mar 31, 2026 | -31.72 Mn |
| Dec 31, 2025 | 24.29 Mn |
| Sep 30, 2025 | 19.67 Mn |
| Jun 30, 2025 | 35.19 Mn |
| Mar 31, 2025 | 20.55 Mn |
| Dec 31, 2024 | 30.78 Mn |
| Sep 30, 2024 | 47.21 Mn |
| Jun 30, 2024 | 35.49 Mn |
| Mar 31, 2024 | 27.76 Mn |
| Dec 31, 2023 | 31.39 Mn |
| Sep 30, 2023 | 31.38 Mn |
| Jun 30, 2023 | 27.53 Mn |
| Mar 31, 2023 | 15.83 Mn |
| Dec 31, 2022 | 16.60 Mn |
| Sep 30, 2022 | 34.61 Mn |
| Jun 30, 2022 | 27.36 Mn |
| Mar 31, 2022 | 22.75 Mn |
| Dec 31, 2021 | 32.05 Mn |
| Sep 30, 2021 | 30.47 Mn |